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The main objective of this project was to develop a drug delivery device that can 
supply medication to the eyes over an extended period without any side-effects.   
The motivation to begin this project came when Dr. Jian-xing Ma, who is director 
of research for the section of Endocrinology at the University of Oklahoma Health 
Sciences Center, Oklahoma City, OK, expressed a need for such a device in order to 
deliver drugs to the eye.  He is a pioneer in the development of angiogenic inhibitors that 
can be used for treatment of diabetic retinopathy and have therapeutic potential for ocular 
neovascular disorders.  If ocular disorders like diabetic retinopathy and age-related 
macular degeneration are diagnosed early, then their progression can be prevented by 
supplying anti-angiogenic agents like Thalidomide to the retina of the eye. The retina lies 
so deep inside the eye that any drug supplied to the surface of the eye rarely cross all the 
layers of the ocular tissue to reach the retina. When the medication is supplied via eye-
drops, it does not stay in contact with the surface of the eye long enough to transport 
across all the layers of the ocular tissue and reach retina.
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Some highly invasive modes of drug delivery like ocular injection and ocular 
implants can be incorporated to deliver the drug to the retina, but due to their invasive 
nature, they suffer from patient incompliance.  Some less invasive modes of drug 
delivery like ophthalmic gels, drug loaded liposomes and nanoparticles, and contact 
lenses soaked in drug solution, provide longer corneal residence time than eye-drops, but 
suffer from various side effects like blurring the vision, burst release of drug, low 
solubility of hydrophobic drugs, and systemic toxicity.   This need of an ophthalmic drug 
delivery system that: (a) can deliver hydrophobic drugs, (b) does not blur vision, (c) 
releases drug slowly over an extended period, (d) does not let the drug be absorbed 
systemically, and (e) does not require surgery, became the motivation and focus of this 
research.  
In the present model, the drug-loaded nanoparticles are incorporated inside a 
collagen-membrane, which a patient can wear in conjunction with any commercial 
contact lens. The lens system will provide a constant contact with the cornea, and the 
particles will supply a continuous release of drug, resulting in more drug reaching the 
target. Only biocompatible and biodegradable materials were used to synthesize the 
nanoparticles and collagenmembranes. The nanoparticles and the membranes were 
characterized for their physical and chemical properties and their suitability for the 







REVIEW OF LITERATURE 
 
2.1 Anatomy of the Eye: 
As shown in figure 1, as light enters the eye, it first passes through a lubricating tear 
film that coats the cornea. The clear cornea covers the front of the eye and helps to focus 
incoming light. After light passes through the cornea it travels through a clear, watery 
fluid called the aqueous humor. The aqueous humor circulates throughout the front part 
of the eye, maintaining a constant pressure inside the eye. The iris is the colored part of 
the eye. As light conditions change, the iris may dilate to make the pupil bigger or 
constrict to make the pupil smaller. This allows more or less light into the eye. After light 
travels through the pupil, it must pass through the lens. The human lens, much like the 
lens of a camera, is responsible for focusing light. The lens can change its shape to focus 
on nearby and distant objects. After being focused by the lens, light passes through the 
center of the eye on its way to the retina. The eye is filled with a clear, jelly-like 
substance called the vitreous. 
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The retina is a thin, light-sensitive tissue lining the back of the eye that acts much like 
film in a camera. Light must be properly focused onto the retina, and the surface of the 
retina must be flat, smooth, and in good working order to produce a clear image. The 
center of the retina is called the macula. The macula contains a high concentration of 
photoreceptor cells which convert light into nerve signals. Because of the high 
concentration of photoreceptors, we are able to see fine details such as newsprint with the 
macula. At the very center of the macula is the fovea, the site of our sharpest vision.  
Behind the retina, a layer of blood vessels called the choroid supplies oxygen and 
nutrients to the outer layers of the retina. The white part of the eye is called the sclera. 
The sclera is composed of tough, fibrous tissue that protects the inner workings of the 
eye. The optic nerve is a bundle of nerve fibers which carries visual information from the 
eye to the brain. 
 




2.2 Posterior Eye Diseases: 
A diseased eye can have problems with anterior or posterior sections of the eye. 
Some of the diseases associated with the anterior section are conjunctivitis, keratitis and 
pterygium, whereas some of the diseases associated with the posterior section are 
diabetic retinopathy, age-related macular degeneration, and glaucoma. The anterior eye 
diseases are relatively easier to treat as compared with posterior eye diseases with the 
help of eye drops. The focus of this research is to supply enough drug to the posterior 
section of the eye in order to treat posterior eye diseases, especially the ones associated 
with retina. 
A very common posterior eye disease is diabetic retinopathy. All diabetics are at risk 
for developing diabetic retinopathy, but not all diabetics do develop it.  Chronic high 
blood glucose levels can damage blood vessels in the retina, and when they are 
damaged, they can leak fluid or bleed. This causes the retina to swell and form deposits. 
This is an early form of diabetic retinopathy called nonproliferative retinopathy.  In a 
later stage, called proliferative retinopathy, new blood vessels grow on the surface of the 
retina. These new blood vessels can lead to serious vision problems because they can 
break and bleed into the vitreous. 
Age-related Macular Degeneration is another posterior eye disease. It leads to loss of 
central vision. New blood vessels grow beneath the macular region of retina and leak 
blood and fluid. This leakage causes permanent damage to light-sensitive cells, which 
die off and create blind spots in the central vision.  
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2.3  Ophthalmic Drug Delivery Vehicles 
Delivery of drug to the posterior section of the eye is one of the biggest challenge we 
face in treating posterior eye diseases.  The most common mode of ophthalmic drug 
delivery i.e. eye-drops is ineffective in supplying desired amount of drug to the posterior 
section of the eye. Some uncommon modes like ophthalmic gels can blur the vision. 
Drug-loaded liposomes and nanoparticles give a burst release of drug requiring frequent 
applications. Inserts require surgery to be placed in the eye. Contact lenses and collagen 
membranes soaked in the drug solution could not be used effectively in the case of 
hydrophobic drugs, due to the low solubility of hydrophobic drugs in the lens matrix. 
Of all the ophthalmic drug delivery systems, nanotechnology-based drug delivery 
system seems to be the most promising, owing to the following properties (a) the 
nanocarriers can protect the encapsulated drug molecule and simultaneously transport it 
to different compartments of the eye, (b) hydrophobic or hydrophilic drugs can be loaded 
into nanocarriers with equal ease by using compatible materials, and (c) the drug-release 
can be controlled by varying the method by which the drug is loaded into the nanocarriers 
and / or the material properties of the nanocarriers. In the following sub-sections some of 
the modes of drug delivery to eyes are explained in detail. 
2.3.1 Eye-drops 
Approximately, 90% of ophthalmic drugs are delivered by aqueous eye-drops [2]. 
There are many problems associated with using eye-drops as a mode of drug delivery. 
Due to tear drainage, there is a short residence time, requiring frequent applications, and 
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leading to only approximately 5% of the drug applied penetrating the outer layer of the 
eye and reaching the target [3]. The use of eye-drops can cause excess drug to be 
absorbed systemically, resulting in possible adverse side effects. For example, the 
delivery of Timolol Maleate, a drug often used to treat open-angle glaucoma, can cause 
cardiac arrhythmias if absorbed systemically [4]. Another limitation of using eye-drops as 
a drug delivery vehicle is the incompatibility of hydrophobic drugs in an aqueous 
medium; restricting the delivery of hydrophobic drugs through suspensions or emulsions.  
2.3.2 Ophthalmic Gels 
Ophthalmic gels are drug formulations with a high percentage of viscosity 
enhancers like cellulose, polyvinylalcohol, or polyacrylic acid.  High viscosity of the gels 
increase the corneal contact time of the drug, and hence improve the bioavailability. 
Examples of ophthalmic gels are Pilopine HS gel, commercialized in 1986 by Alcon, and 
Timoptic-XE by Merck. On the downside, gels not only blur the vision, but can only 
improve the bioavailability to a limited extent and dosing can be decreased to once a day 
at most [5].   
2.3.3 Drug Loaded Liposomes 
Liposomes are microscopic bubbles, which are formed when phospholipids that 
have a hydrophilic head and a hydrophobic tail align themselves in such a way that a 
concentric bi-layer is formed, as shown in figure 2. These bubbles or vesicles are 
separated by water or aqueous buffer and range in diameter from 80 nm to 10 µm.  
Liposomes (also called phospholipid vesicles) were first described by Bangham et al [6]. 
These vesicles can entrap both hydrophobic and hydrophilic drug molecules. Some of the 
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advantages of using liposomes for ocular drug delivery are (i) hydrophobic drugs can be 
delivered, (ii) drug can be delivered in the form of liquid drops just like eye-drops, (iii) 
drug delivery is more controlled and prolonged than eye-drops, and (iv) drug metabolism 
by the enzymes present at the tear / corneal epithelial surface is prevented [7].  
The major disadvantage of liposomal drug delivery is the burst release of drug 
that necessitates frequent applications. Liposomes can be modified in order to prolong the 
drug release. Two of the modifications that prolonged the delivery of acetazolamide to 
the eye were (a) introduction of multi layers of phospholipids, and (b) introduction of a 
charge density to the phospholipids [8]. In spite of the modifications, the drug delivery 
was prolonged only up to nine hours, indicating an opportunity to create a better mode of 
drug delivery that can deliver the drug for longer periods. 
 
  




2.3.4 Drug Loaded Nanoparticles 
Drug loaded nanoparticles are polymeric particles of diameter between 1 nm and 
1000 nm that serves the purpose of delivering drug molecules to the body. Drug 
molecules can be small molecules like aspirin with a molecular weight of 180.2 Da or 
large molecules like avastin, a recombinant humanized monoclonal IgG1 antibody with 
molecular weight of 149 kDa. The drug molecules can be either contained within the 
particle or be conjugated to the surface of the particle. The drug molecules can be 
formulated at a nano-scale so as to function as their own “carriers” [10-14].   
There are various ways to introduce drug-loaded nanoparticles into the body. 
When introduced intravenously, due to their small size, nanoparticles do not form an 
embolism even in the smallest capillaries, which are 5–6 µm in diameter [15].  In the case 
of oral drug delivery system, the main focus of research has been in lymphatic uptake of 
the nanoparticles by the Peyer’s patches in the gut associated lymphoid tissue. The size 
and surface charge of the nanoparticles have been found to influence the uptake. The 
nanoparticles were found to disseminate systemically, whereas the microparticles were 
found to remain in the Peyer’s patch [15-18]. In case of ocular drug delivery, 
mucoadhesive copolymeric micelle nanoparticles were also found to increase the 
bioavailability of some drugs by increasing the corneal contact time [19]. Although the 
use of nanoparticles for ocular drug delivery seems to be very promising, at present it 
needs improvement in a number of fronts including formulation stability, control of 
particle size, control of the rate of drug release, and large scale manufacturing of  sterile 
preparations [20].  
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2.3.5 Ocular Inserts 
Ocular inserts come in various sizes and shapes. Solid inserts like Ozurdex, an 
intravitreal implant can deliver an extended release of corticosteroid to the back of the 
eye [21]. It is administered via an intravitreal injection. It uses a biodegradable, solid 
polymer delivery system that is capable of maintaining a low level of dexamethasone 
over extended period thereby controlling edema and enhancing safety. Lacrisert, a small 
capsule used for dry-eye relief, can be placed in the lower eye lid of the patient by oneself 
[22].  Surodex, a dexamethasone delivery system that uses erodible-implant technology is 
approved in Singapore. It has an advantage of not requiring surgical excision after its 
contents are exhausted [23].  Some other types of inserts are membrane-controlled 
diffusional inserts, hydrophilic but water-insoluble inserts, and erodible inserts [24]. 
Owing to their strategic location, i.e. inside the eye, inserts can be used for controlled 
delivery of the drug.  In spite of this advantage, patient compliance towards ocular inserts 
have always been low due to the surgery involved in placing the insert, difficulty with 
self insertion, and the feeling of a foreign body in the eye. Examples of some of the 




Figure 3. Examples of ophthalmic delivery systems [23]. (a) Photograph of patient with 
Ocusert (pilocarpine) in place in lower cul-de-sac of right eye. (b) Photograph of use of 
fluorescein lyophilized on Teflon strips. Photograph courtesy of Prof. Michael 
Diestelhorst. (c) Encapsulated cell technology: schematic diagram of implant. (d) 
Encapsulated cell technology: schematic diagram of implant placed in vitreous cavity of 
human eye. Photograph courtesy of Neurotech, Inc. (e) Iluvien fluocinolone acetonide 
implant. Photograph courtesy of Alimera Sciences. 
 
2.3.6 Contact Lenses Soaked in Drug Solution 
A number of attempts have been carried out to deliver drug to the eyes by 
entrapping the drug on to soft contact lenses via soaking it in drug solution followed by 
insertion into the eye [25-27].  Contact lenses soaked in drug solution, when worn by a 
patient, marginally increase the corneal contact time. Hehm, EM et al. compared in vivo 
release of five different aminoglycosides and fluoroquinolones through contact lenses 
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soaked in drug solution with their release through eye drops [28]. They concluded that 
the amount of drug released by the lenses is lower, or of the same order of magnitude, as 
the amount of drug released by eye-drops. There are some major limitations that contact 
lenses soaked in drug solution suffer. After placing the drug soaked lens into the eye, all 
the drug diffuses into the eye within a few hours, rendering it inapplicable for controlled 
release. After placing the lens in aqueous drug solution, it takes a few hours for the drug 
to load on to the lens and the large fraction of the drug that is left in the solution is 
wasted. The drug loading of the lens depends upon the solubility of the drug into aqueous 
media, rendering this technology inapplicable to hydrophobic drugs. 
2.3.7 Contact Lenses Embedded with Drug-Loaded Nanoparticles 
Gulsen and Chauhan developed a contact lens embedded with drug-loaded 
nanoparticles as shown in figure 4. They used lidocaine as a model drug and prepared 
nanoparticles with OTMS (octadecyltrimethoxysilane). They synthesized the particle 
loaded p-HEMA hydrogels by free radical solution polymerization of the monomer with 
chemical initiation.  In vitro drug release experiments were carried out in water at pH of 
6.5. It was concluded from the drug release studies that 1-mm thick hydrogels loaded 
with nanoparticles can deliver hydrophobic drugs for three to four days. The main 
drawback of this delivery system was that the drug release rate decreased exponentially 
after the initial burst release [29]. An improved system would include (a) minimal burst 
release, (b) sustained drug release rates, and (c) focusing the drug-release only to the 
inside i.e. towards the cornea, instead of releasing the drug to the conjunctiva. This would 
lead to (a) a higher concentration gradient at the cornea-lens interface resulting in higher 
drug diffusion into the eye (b) a reduction of any drug-drainage into the lachrymal duct, 
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and hence reducing any side-effects due to systemic absorbance of the drug, and (c) an 
increase in the overall release time. 
    
Figure 4. Contact Lens Embedded with Drug-Loaded Nanoparticles [29] 
 
 
2.4 Development of a Novel Nanotechnology Based Ophthalmic Drug Delivery 
Device 
For this study, we investigated a design composed of lidocaine-loaded, PLGA 
poly(lactic-co-glycolic acid) nanoparticles suspended within a transparent, ultrathin 
collagen membrane that can be attached to a standard commercial-grade contact lens for 
support, as shown in figure 5. The lens system will provide constant contact with the 
cornea, and the particles will supply a continuous release of drug, resulting in more drug 
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reaching the target. Lidocaine was selected as the model drug, since it is a hydrophobic 
drug that has extensively been investigated in other ophthalmic drug delivery systems 
[29]. The nanoparticles were synthesized with PLGA polymer, due to its biodegradable 
and biocompatible nature, and the fact that it has already been used to deliver a variety of 
therapeutic agents by targeted and/or sustained delivery.[30-32]. Collagen – type 1,  the 
most abundant collagen of the human body which is found in tendons, skin, artery walls, 
and the organic part of bones and teeth was selected due to the following properties: 
transparent, malleable, high tensile strength, biocompatible, and biodegradable. 
Moreover, after drying, it can be rehydrated just by adding equal amount of water, 
making it suitable for dry storage. 
Using various analytical techniques, the characterization of the nanoparticles was 
carried out by examining the morphology, size, and drug-loading. The collagen 
membranes were characterized by examining the morphology, mechanical strength, and 
light transmittance. Drug release rate of the complete lens system was characterized and 
compared to drug-infused nanoparticles and drug-infused collagen membranes.  
 
Figure 5. Details of Novel Ophthalmic Drug Delivery Device
 
2.5  Model Drug Selection
The model drug, lidocaine was selected based on its physical and chemical 
properties. Its empirical molecular formula is
and molecular structure is as shown in figure 6. Its use as a local anesthetic agent in 
ophthalmology, specifically during ocular surgery has been widely studied and proved 
[33].  It is an important class 1B antiarrhy
ventricular arrhythmias.  It has also proved effective in treating jellyfish stings 
use in humans has been very well studied.
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C14H12N2O, molecular weight is 234.34 Da, 




[34].  Its 
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Most of the ophthalmic drugs like metipranolol, epinephrine, dichlorphenamide, 
and lidocaine are hydrophobic in nature i.e. they are either insoluble or sparingly soluble 
in water, which makes them hard to be delivered via aqueous eye-drops. By conjugating 
these molecules with an acid improved their solubility in water. For example 
metipranolol hydrochloride, epinephrine d-bitartrate, and lidocaine hydrochloride are 
hydrophilic and therefore are soluble in water. In some cases where conjugation is not 
possible or where the efficacy of drug is compromised due to conjugation it is imperative 
to utilize a non-conventional mode of drug delivery to deliver the drug in its original 
form. In this study a hydrophobic drug, lidocaine was loaded into nanoparticles that can 
be delivered to the eyes via a collagen membrane. 
 






2.6  Drug Stability 
The stability of the drug is of concern during the synthesis process and during the 
drug-release study.  If the drug decomposes or metabolizes during either of these steps, 
the results of this study would be inconclusive. The drug molecules undergo temperature 
changes and interact with organic solvents, which might affect the stability of the drug.  
A couple of experiments were conducted in order to establish stability of 
lidocaine in the present matrix and under the elevated temperature and pH conditions.  
The stability of lidocaine in various other matrices that consisted of excipients, fillers and 










MATERIALS AND METHODS 
 
3.1 Reagents 
Poly(lactide-co-g lycolide) Acid (PLGA) (50:50) and Poly(vinyl alcohol) (PVA), 
87-90% hydrolyzed, MW 30k – 70k were purchased from Sigma-Aldrich (St. Louis, 
MO). Lidocaine U.S.P. was purchased from Spectrum (Gardena, CA). Ethyl Acetate 
(HPLC-UV grade) was purchased from Pharmco (Brookfield, CT). Purified Bovine 
Collagen solution (type 1) was purchased from Advanced Biomatrix (San Diego, CA). 
PBS (Phosphate Buffer Saline) solution, pH 7.4 was prepared from salt that that was 
purchased from Invitrogen. Ethyl Alcohol was purchased from Pharmco (Brookfield, 
CT). All other chemicals and solvents used were purchased from local suppliers and of 





3.2  Synthesis of Lidocaine Loaded Nanoparticles 
All the procedures were carried out in a well ventilated hood.  PLGA (50:50) was 
removed from cold storage at 4 °C and let it sit for approximately one hour to come to 
room temperature. This was done to avoid any moisture that might accumulate on the 
cold powder when the bottle is opened. A 1.0% (w/v) PVA solution (MW 30k – 70k, 87 
– 90% hydrolyzed) was prepared in a 250 ml beaker by dissolving 1500 mg of PVA in 
150 ml water and mixing at 200 rpm on a stir plate for 2 hours. Inside a 100 ml sample 
bottle with cap, 1500 mg PLGA (50:50) was dissolved in 50 ml ethyl acetate.  Inside a 50 
ml sample bottle, 750 mg lidocaine was dissolved in 25 ml ethyl acetate.  Finally the 
contents of 50 ml sample bottle were added to 100 ml sample bottle and gently shaken in 
order to mix.  The PVA solution was placed on an ice bath and the tip of sonicator probe 
(Fisher Scientific Sonic Dismembrator Model 500) was inserted to a depth of half the 
height of the solution.  With sonication at 75% of total intensity, the organic solution 
from the previous step was slowly added using a 1 ml pipette.  Within 10 minutes, all the 
organic mixture was added to the aqueous solution leading to the formation of 
nanoparticles (figure 7a). The contents were transferred to a 1000 ml beaker and stirred at 
200 rpm on a magnetic stir plate for 10 hours, to evaporate the organic solvent i.e. ethyl 
acetate (figure 7b). After 10 hours, 200 ml of DI water was added to the contents and 
stirred at 200 rpm on magnetic stir plate for 5 minutes.  The contents were filtered 
through a 1.2 µm filter (Fisherbrand G4) using a vacuum filtration unit. 
The filtered solution was collected in eight 50 ml centrifuge tubes (Nalgene Oak 
Ridge Centrifuge tube, PPCO) and as suggested by T Gorner et al. [37], it was 
centrifuged at 16,000 g and 4 °C for 25 minutes with a high speed centrifuge (Sorvall 
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Instruments, Dupont, RC5C, figure 7c).  The supernatant was collected in a separate 
container leaving 10 ml solution behind.  This solution was re-suspended in 40 ml fresh 
DI water.  The steps of centrifugation and re-suspension were repeated until the 
supernatant became transparent, indicating the removal of PVA. One milliliter of the 
supernatant that was collected above was withdrawn, stored and later, analyzed for the 
amount of lidocaine using gas chromatography. This helped in assessing the drug loss 
during the synthesis process.  
After the last centrifugation the particles were re-suspended in 6 ml water and 
agitated to get an even suspension.  By this step the PVA and ethyl acetate had been 
completely removed from the nanoparticles.  One ml of suspension was added to six pre-
weighed and pre-marked 2 ml vials. These vials were placed inside an isopropyl alcohol-
jacketed container (Nalgene Cryo 1° C Freezing Container) placed in a -80 °C freezer for 
10 hours.  This container is used to freeze the suspension slowly at a rate of minus 1 °C 
per minute, prior to freeze drying.  Slow cooling of the suspension prevents unwanted 
agglomeration of the particles that might occur if cooled too quickly. The frozen 
suspension of nanoparticles was lyophilized (freeze dried) for 12 hours (figure 7d).  The 
dried nanoparticles in the vials were re-weighed and used for characterization studies and 




a. Ethyl acetate 
containing PLGA : 
lidocaine (2:1) was 
added dropwise to 
1% PVA solution 
while sonicating. 
b. The suspension 
was stirred on a 
magnetic stir plate 
for 10 hours in order 
to evaporate the 
ethyl acetate. 
 




centrifuging at 4 ̊C 




d. The concentrated 
suspension was 
lyophilized for 12 
hours to obtain the 
nanoparticles in dry 
powder form. 
 
Figure 7. Steps Involved in the Synthesis of Lidocaine-Loaded Nanoparticles 
 
 
3.3 Synthesis of Collagen Membranes 
Under a class II A2 biological safety cabinet, a collagen solution for preparation 
of the membranes was prepared by combining of  purified bovine collagen solution 
(3mg/ml), 10x PBS solution, and 0.1 N sodium hydroxide at 57.1% : 7.2% : 35.7% by 
volume, respectively.  The collagen solution was mixed with nanoparticles to make the 
final concentration of 1.5 mg nanoparticles per ml of collagen solution (figure 8a).  The 
remaining solution was used to make collagen shields without nanoparticles.  Both 
solutions with and without nanoparticles were poured into wells of two separate six well 
plates at 1502 µL per well.  Both plates were covered and incubated at 37 °C in a CO2 
incubator for one hour to gel the collagen (figure 8b).  With the help of a pair of tweezers, 
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the gels were removed from each well, spread on a Teflon sheet, and left for 10 hours to 
dry under room temperature in a biological safety cabinet (figure 8c and 8d).  After 
drying, the collagen membranes were removed carefully from the Teflon sheet, weighed 
and stored inside 2 ml vials, until further analysis. 
  Lidocaine-loaded collagen membranes were prepared by adding 0.07765 mg 
lidocaine per ml collagen solution instead of loading nanoparticles. The 0.07765 mg / ml 
is equivalent to the amount of lidocaine loaded on nanoparticle-loaded membranes, which 
contain 1.5 mg nanoparticles per ml of collagen solution and the average lidocaine 
loading on the nanoparticles is 5.18%.  
 
a. Collagen (type 1 
bovine) was mixed 





ml) was added to 
each well of a six-
well plate and   
incubated at 37 °C 
for 1 h to gel. 
c. The collagen gels 
were carefully 
removed from the 
wells. 
d. The gels were 
spread on a 
Teflon-sheet and 
allowed to dry 
overnight at room 
temperature. 





3.4 Size and Morphology 
 
The size of the nanoparticles was measured by running a 1 % (wt/vol) suspension 
of nanoparticles in water through a dynamic light scattering machine, Malvern HPPS – 
5001 Particle-sizer. 
The morphology of nanoparticles and collagen membranes was analyzed by using 
a scanning electron microscope (SEM; Quanta 600F, FEI, Hillsboro, OR).  The 
nanoparticle samples for SEM analysis were prepared by drying a drop of nanoparticle 
suspension on a metal stub and sputter coating a thin layer of gold onto the sample for 30 
seconds. The collagen membrane samples were prepared by spreading the membrane 
over a carbon coated stub and sputter coating with gold. The morphology of the collagen 
membranes embedded with nanoparticles was compared with those that were synthesized 
without nanoparticles by using SEM.  The nanoparticle size distribution was also 
calculated by analyzing the SEM pictures by an image analysis software called ImageJ.  
The morphology of the membranes was also studied by taking full view pictures 
of the dry and wet membranes with a 10X digital microscope (Olympus SZX9, Tokyo, 
Japan). The membranes were sandwiched between two glass cover slips, the distance of 
microscope lens was adjusted to bring the picture in focus, and the pictures were taken by 
a computer-controlled camera that was attached to the microscope. 
 
3.5 Visible Light Transmittance 
Since the proposed drug delivery system is designed as a lens system for the eye, 
it must not interfere with the normal vision of the eye. In order to evaluate the 
transparency of the membranes, an analysis was conducted to determine the amount of 
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visible light transmitted through the collagen membranes. Collagen membranes were 
immersed in 1 ml PBS and added to a 24-well plate. The optical density of the samples 
was measured at several wavelengths by using a spectrophotometer (SpectraCount, 
Packard). Optical density was measured for the following samples: (1) a collagen 
membrane loaded with nanoparticles that has been in PBS solution for five minutes, (2) a 
collagen membrane loaded with nanoparticles that has been in PBS solution for fifteen 
days: to investigate the effect of wetting with PBS over time, (3) a collagen membrane 
without nanoparticles that has been in PBS solution for five minutes: to investigate the 
effect of the presence of the nanoparticles, (4) a blank 1 ml PBS solution, and (5) a 
commercially available contact lens (BC: 8.6, DIA : 14.2, PWR : -0.25, Proclear, 
CooperVision, Scottsville, NY): to be able to compare the transmittance of light through 
a standard device. 
 
 
3.6 Tensile Strength 
 
A Tensile Strength test was conducted on collagen membranes in order to 
quantify the mechanical strength of the membranes. The mechanical strength can be 
related to the structural integrity of the membrane, which is also tied to the degradation of 
the membrane. The membrane was cut into 1 cm x 2 cm rectangular piece and clamped 
onto the tensile testing machine (Instron 5542, Norwood, MA). Tensile stress in MPa was 
plotted against percent strain when an elongation of 1 mm per minute was applied to the 
sample. The tensile strength of a collagen membrane containing nanoparticles was 




3.7 Chromatographic Analysis of Lidocaine 
The drug-loading and drug-release samples were analyzed for lidocaine by gas 
chromatography.  For drug-release, the standards were prepared in 50% ethanol solution, 
and the samples were collected from PBS solution.  For drug-loading, the standards and 
samples were both prepared in ethyl acetate.  The following GC method was developed 
on Agilent 6890 GC machine based on work of Mohammed Abdel-Rahim et al [38].  
a) Injector: Temperature = 250 °C,  
b) Splitless mode with purge activation time at 1 min 
c) FID Detector: Temperature = 305 °C 
d) GC Column: SPB-50 Supleco 30 m * 0.25 mm * 0.25 µm 
e) Oven Temp Gradient:  
• Start     -      100 °C – 1 min 
• 50 °C/min – 200 °C – 0 min 
• 20 °C/min – 295 °C – 3 min 
f) Injection Volume: 0.5 µL 
g) Flow rate of carrier gas through column: 2 ml/min 
A standard linearity curve between area under the peak and concentration in µg/ml, 
with R-square value of more than 0.99 was drawn by running 40, 100, and 200 µg/ml  






3.8 Drug Stability 
The stability of the drug, lidocaine was investigated in two scenarios: first, 
thermal stability at 37 °C and pH 7.4, and second, compatibility with ethyl acetate. 
The drug-release study is carried out at 37 °C, hence any thermal instability of the 
drug molecules would render the study-results inconclusive. The thermal stability of 
lidocaine was assessed by carrying out an experiment in which 100 mg of lidocaine was 
dissolved in 2 ml ethanol and diluted to 100 ml with PBS solution. One ml of this 
lidocaine solution was poured into 24 vials each and stored at -20 °C. At each time point: 
0, 14, 28, 42, 56, and 70 days, three vials were withdrawn and mounted on a rotary 
shaker at 37 °C. At the end of 70 days the concentration of lidocaine was measured in all 
the vials using gas chromatography.  
The process of nanoparticle-synthesis involves dissolving the drug in an organic 
solvent, ethyl acetate. An experiment was conducted to check the stability of lidocaine 
during its interaction with ethyl acetate. A 1% solution of Sigma reference standard 
lidocaine in ethyl acetate was prepared and then ethyl acetate was removed by 
evaporation. IR spectra were measured on Scimitar Series model Varian 800 FTIR 
spectrometer in the wave number region 400-4000 cm-1.  All IR measurements were 
carried out at room temperature using the KBr pellet technique.  The IR spectrum of 
residual lidocaine was produced and compared with the standard lidocaine using 







3.9 Drug Loading 
 
Approximately 10 mg of nanoparticles were dissolved in 3 ml ethyl acetate and 
analyzed by GC for lidocaine concentration. The sample solutions were passed through a 
1 cm column of activated basic Aluminum Oxide in order to remove PLGA, and hence 
prevent the deposition of PLGA polymer inside the GC column (figure 9a and 9b). A 
standard linearity curve between area under the peak and concentration in µg/ml, with R-
square value of more than 0.99 was drawn by running 40, 100, and 200 µg/ml   standards. 
Concentration of the drug in the samples was calculated by interpolation. Drug-loading 
was calculated by factoring the dilution of the sample into the concentration of the drug 
from the standard curve. 
a. 1 cm column of activated basic 
Aluminum Oxide 
 
b. Drug-solution collected 
in 1.5 ml vial 




3.10 In vitro Release of Lidocaine 
 
To measure the release of lidocaine from the nanoparticles, 10 mg of 
nanoparticles were suspended in 1.5 ml of PBS solution and shaken (Hand-motion 
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shaker; Scinics, Tokyo, Japan) at 60 rpm at 37 °C, in order to mimic physiological 
conditions.  At the following time points, a 30 µL sample was withdrawn and 30 µL of 
fresh PBS was added: 1, 3, 6, 12, 24, 48, 168, and 408 hours.  The samples were filtered 
through a 0.1 µm filter to remove any nanoparticles and thereby avoid any drug 
contribution from the nanoparticles.  All the samples were stored at -20 °C until ready for 
analysis. 
To measure the release of lidocaine from collagen membranes, a membrane was 
placed inside a vial containing 1.5 ml PBS and shaken at 60 rpm at 37 °C.  At the 
following time points, a 30 µL sample was withdrawn and 30 µL of fresh PBS was 
added: 1, 3, 6, 12, 24, 48, 168, and 408 hours.  The samples were filtered through a 0.1 
µm filter to remove any nanoparticles and thereby avoid any drug contribution from the 
nanoparticles.  All the samples were stored at -20 °C until ready for analysis.  Three 
batches of membranes, each consisting of three membranes containing a single batch of 
nanoparticles were simultaneously tested against one batch of three membranes that 
contained an equivalent amount of drug, but no nanoparticles.  All the samples collected 







RESULTS AND DISCUSSION 
 
4.1 Size and Morphology: 
 
SEM pictures of nanoparticles showed an irregular shape and mean particle 
diameter of approximately 247 nm as calculated by the image analysis software ImageJ 
(http://rsbweb.nih.gov/ij/download.html).  An SEM image of nanoparticles like the one 
shown in figure 10a is cropped and inverted by ImageJ as shown in figure 10b.  Scale is 
set based on SEM image, sphericity is set to one, threshold is adjusted accordingly and 
the particles are analyzed for their size and shape by drawing their perimeter as shown in 
figure 10c.  By using the “Particle Analysis” function of ImageJ, the size distribution of 
the particles in a spreadsheet format was also obtained as shown in appendix A. 
30 
 
The average size of nanoparticles as measured by Malvern HPPS – 5001, an 
instrument based on dynamic light scattering, was found to be in the range of 150 nm and 
300 nm. As shown in figure 11a, the vital parameters of the system were chosen to be the 
following: water as dispersant with refractive index 1.330 and viscosity 0.8872 cP, PLGA 
as the nanoparticle-material with refractive index 1.45, and temperature as 25 °C. A 
logarithmic size-distribution curve and a histogram showing the particle size distribution 
was generated by the machine (figure 11b and 11c). The DLS results for all the three 
batches are shown in appendix A.  The mean particle diameter measured by SEM was 
within range of the size distribution measured by dynamic light scattering, confirming the 
mean particle size. 
Nanoparticle-loaded collagen membranes are white to colorless, ultrathin, 
circular, sheets of collagen of approximately 1 cm in diameter.  Some characterization 
techniques required larger samples for analysis.  Therefore, the diameter of the 
membranes that were prepared for the drug-release study and tensile strength was 2.5 cm. 
The SEM pictures of the nanoparticle-loaded membranes showed an uneven 
distribution of particles on the membrane-surface, forming some regions with higher 
density of particles than others (figure 12a and 12b). In the regions of low particle 
density, collagen fibers were very prominent and looked quite similar to the ones in the 
nanoparticle-free membranes (figure 12c).  In the regions of high particle density, the 
nanoparticles were more prominent on the surface and collagen fiber structures were 
hidden below.  As shown in appendix B, assuming sphericity of the particles as one, the 
average size of nanoparticles measured by ImageJ from these pictures was 56.89 ± 1.36 
nm.  One possibility is that the larger diameter particles were embedded within the 
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membrane, while the smaller diameter particles remained on the surface of the 
membrane. 
The pictures of collagen membranes taken by a stereomicroscope at 10x revealed 
that on wetting, the membranes rearranged their fibers in such a way that they become 
transparent again (figures 13a and 13b). The thickness of the membranes was found to be 
in the order of 50 microns. 
a. SEM image of 
nanoparticles 
b. SEM image of 
nanoparticles after 
processing by ImageJ 
c. Perimeter representation 
of the particles by ImageJ 





a. System parameters 
b. Logarithmic size distribution curve 
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c. Statistical analysis of nanoparticle size 




a. A region of a collagen 
membrane containing 
numerous nanoparticles on 
the surface 
Figure 12. SEM Images of





4.2 Transparency of Membranes
 
Figure 14 shows t
as measured by UV-is spectrophotometer
the membranes with nanoparticles
slight decrease in transmitta
Scale = 1 cm
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b. A region of the same 
collagen membrane 
containing very few 
nanoparticles on the surface 
c. Collagen fibers of a 
nanoparticle





b. Structures of collagen fibers disappear when 
membrane is wetted
Pictures of Collagen Membranes with 10 X Camera
 
he results of the visible light transmittance of the samples tested, 
.  The mean % transmittance of light through 
 decreased from 88 to 81 over a period of 
nce could be due to the membrane degrading, resulting in 
 









realignment of the collagen fibers, which could block the transmittance of light.  Mean % 
transmittance of light through membranes without nanoparticles is 91, which is slightly 
higher than those with nanoparticles. This shows that nanoparticles slightly decreased the 
transparency of the membranes. Proclear (Omafilcon A), a commercially available 
contact lens, has a % transmittance of 96, which is almost equal to the % transmittance 
through the blank sample (1 ml PBS).  
 
Figure 14. Transparency of Membranes With and Without Nanoparticles, Compared to the 
Control Samples of PBS and a Commercially Available Contact Lens.  Data shown are mean 
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4.3 Tensile Strength 
Tensile strength of collagen membranes containing nanoparticles was compared 
with membranes without nanoparticles, both without wetting and after wetting in PBS for 
12 days.  For without wetting, until fracture point is reached, the amount of strain was 
higher for collagen membranes loaded with nanoparticles than the membranes without 
nanoparticles, when same amount of stress was applied on membranes (figure 15a). The 
membranes without nanoparticles could bear more mechanical stress (10.8 MPa as 
compared to 5.1 MPa) as well as more strain (3.8% as compared to 2.7%) before 
breaking. An explanation of this behavior could be that in the presence of nanoparticles 
the collagen fibers are not able to fully align themselves when under stress, resulting in 
lower tensile strength. On the other hand, when the membranes were wetted with PBS for 
12 days, their mechanical strength was reduced considerably (figure 15b). Both the 
membranes with nanoparticles and those without nanoparticles behaved identically, and 
could not bear a tensile stress of more than 0.07 MPa.  The reduction in mechanical 





a. Tensile strength of dry collagen membranes 
 
b. Tensile strength of collagen membranes wetted in PBS for 12 days 
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Collagen membrane containing 
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4.4 Chromatographic Analysis of Lidocaine 
As shown in figure 16, a standard linearity curve between area under the peak and 
concentration of lidocaine in µg/ml, with R-square value of more than 0.99 was drawn by 
running 40, 100, and 200 µg/ml   standards. Concentration of the drug in the samples was 
calculated by interpolation from this standard curve.  
 
Figure 16. Standard Linearity Curve for Lidocaine Analyzed on GC (Agilent 6890). 











































4.5 Drug Stability 
The drug, lidocaine, was found to be stable in both the scenarios tested: (a) at 37 
°C in the presence of PBS and (b) after interaction with ethyl acetate. The results of the 
thermal stability test, as shown in figure 17, indicate that at an elevated temperature of 37 
°C and in the presence of PBS solution, lidocaine does not degrade or decompose. At all 
time points, the concentration of lidocaine remained 1000 µg/ml ± 8%, which was within 
the experimental error range. 
The FTIR spectrum produced from ethyl acetate-treated lidocaine showed 
identical peaks as untreated lidocaine. There was a slight peak mismatch at wavenumber 
of 2360, but it is believed to be from CO2 contamination from air.  This is shown in 
figure 18a, which is an overlap spectrum achieved by using “compare” function of the 
Perkin Elmer’s FTIR machine. The overall match between the two spectra from the 
“compare” function was higher than 95%.  This proved that the lidocaine molecule does 
not change structurally after treatment with ethyl acetate. It also confirmed that the results 
of the drug release study are not affected by the stability of the drug. The spectra in 
figures18b and 18c represent background from KBr pellet and lidocaine reference 
standard respectively.   
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Figure 17. Drug Stability in PBS at 37 °C. Data shown are mean values ± sd; n=3 
 
 































b. Background spectrum from KBr pellet 
 
c. Lidocaine reference standard from Sigma Aldrich 
Figure 18. FTIR Spectrum of (a) Lidocaine Sample Compared to Ethyl Acetate-Treated 






4.6 Drug Loading 
 
The percent (weight of drug / weight of nanoparticles) of lidocaine loaded in the 
nanoparticles, was measured to be 5.17% ± 0.88%. Based on 2.253 mg of nanoparticles 
per collagen membrane, the concentration of drug per membrane, in the units of µg of 
drug / membrane, was theoretically calculated to be 116.63 ± 17.12.  
 
4.7 Drug Release 
The in vitro drug release from nanoparticles and collagen membranes was studied 
by monitoring the increase in the concentration of the drug in a constantly stirred beaker 
over time. The drug release profile from collagen membranes containing nanoparticles 
was compared to nanoparticles only and to collagen membranes containing an equivalent 
amount of drug but no nanoparticles (figure 19). In the case of nanoparticles only, a burst 
release of drug was noted.  Within one hour of the release experiment, all the drug 
adsorbed to the surface of nanoparticles was released and percent drug release rose to 
41.8%. Within 12 hours of the release experiment, the percent drug release rose to 53.6 % 
and remained at that level until 48 hours.  A possible explanation could be that the drug 
reached its solubility limits in aqueous media and could not diffuse any more.  After that 
the nanoparticles seem to erode and the process of dissolution took over diffusion, and 
the concentration rose to 64% at 168 hours time point.  In case of membranes containing 
drug but no nanoparticles, the percent drug release rose to only 3.1% in the first three 
hours and reached a maximum of 8.6% in 24 hours. Such a low drug release could be 
attributed to the drug interacting either physically or chemically with the collagen 
membrane, thus preventing it from being released into the aqueous environment.  The 
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drug release from collagen membrane containing drug-loaded nanoparticles reached 16.2 
% in one hour and then steadily increased to 23.4% over the next seven days. This kind 
of drug release profile is highly desired from any sustained release drug delivery device 
because it helps in quickly reaching the therapeutically effective level and then sustaining 
it for extended period.  
 
Figure 19. Comparison of Drug Release Profiles from Three Different Systems. Data shown 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 CONCLUSIONS  
The main objective of this research was to develop an ocular drug delivery device 
that is capable of consistently delivering the drug over an extended period. The proposed 
design consisted of a collagen membrane embedded with lidocaine-loaded PLGA 
nanoparticles.  The drug release profile of nanoparticles only, showed a burst release of 
drug.  The drug release profile of a collagen membrane loaded with drug showed a low 
level of the drug released over the time period tested.  Only the collagen membranes 




The physical characteristics of the device indicate a feasible commercialization of 
the device in the future. The device can be loaded with a hydrophobic or hydrophilic drug 
with equal ease. It can be stored in a dry place and wetted just before insertion into the 
eye. Although, the tensile strength of the membrane seems to be high enough to 
withstand the shear stress due to eye-lid movement, it will only be accurately determined 
after in vivo studies. The light transparency of the membrane was found to be slightly 
lower than commonly used contact lens but whether or not this transparency is acceptable 
to patients will only be determined after in vivo experiments. To some extent 
transparency can be controlled by controlling the number of nanoparticles per collagen 
membrane. The diameter of the membrane can be varied according to the need by 
varying the amount of collagen.  
In comparison with other already existing technologies, this device can be 
expected to deliver the drug for a longer period without any invasive procedure and with 
minimal drug wastage. Collagen membrane embedded with nanoparticles not only 
overcomes all the limitations of eye-drops, but also inherits minimal side effects that are 
associated with other drug delivery devices.  Collagen membranes do not blur the vision 
like ophthalmic gels do. They can be used to deliver hydrophobic or hydrophilic drugs 
with equal ease. They can be stored in a dry environment for a long time, unlike some 
nanoparticle formulations. They do not require a surgery to be placed inside the eye like 





5.2 Future Directions 
A study to determine drug-loading of collagen membranes containing 
nanoparticles and and of collagen membranes containing equivalent amount of drug 
would be highly recommended in the future.  It will increase our confidence in the 
percent drug release results. In the present study the percent drug release results were 
based on theoretical drug loading, which was calculated from the amount of nanoparticles 
loaded onto collagen shield and drug loading onto nanoparticles.  
In the future, in vivo testing of this device will help in predicting (a) the in vivo 
drug release profile (b) the level of eye-irritation after wearing the device (c) the 
acceptability of compromised light- transparency (d) the oxygen and carbon dioxide 
permeability through the lens-membrane system. Developing a mathematical model to 
predict the drug release through these membranes will help in optimizing some of the key 
parameters like size of nanoparticles, number of nanoparticles per membrane etc.  The 
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SEM image of nanoparticles 
  
SEM image of nanoparticles after 
processing by ImageJ 





Region 1 Contd… 
 
Size Distribution of nanoparticles: 
 
Area Dia Count Dia * Count 
1023 36 94 3384 
2394 55 39 2145 
3765 69 21 1449 
5136 81 7 567 
6507 91 4 364 
7878 100 2 200 
9249 109 2 218 
10620 116 1 116 
11991 124 2 248 
13362 130 1 130 
14733 137 2 274 
16104 143 2 286 
17475 149 0 0 
18847 155 0 0 
20218 160 0 0 
21589 166 1 166 
22960 171 0 0 
24331 176 1 176 
25702 181 0 0 
27073 186 1 186 
Total = 180 9909 







SEM image of nanoparticles 
  
SEM image of nanoparticles after 
processing by ImageJ 






Region 2. Contd… 
 
Size Distribution of nanoparticles: 
 
 Area Dia Count Dia * Count 
1023 36 235 8460 
2423 56 78 4368 
3824 70 38 2660 
5224 82 22 1804 
6625 92 19 1748 
8025 101 12 1212 
9426 110 8 880 
10826 117 5 585 
12227 125 4 500 
13627 132 2 264 
15028 138 2 276 
16428 145 0 0 
17829 151 0 0 
19229 157 3 471 
20630 162 4 648 
22030 168 1 168 
23431 173 0 0 
24831 178 2 356 
26232 183 1 183 
27632 188 1 188 
Total = 437 24771 




   






SEM image of nanoparticles 
SEM image of nanoparticles after 
processing by ImageJ 






Region 3. Contd… 
 
Size Distribution of nanoparticles: 
  Area Dia Count Dia * Count 
1023 36 128 4608 
2229 53 40 2120 
3436 66 25 1650 
4643 77 16 1232 
5850 86 12 1032 
7057 95 7 665 
8264 103 7 721 
9471 110 7 770 
10677 117 3 351 
11884 123 1 123 
13091 129 2 258 
14298 135 3 405 
15505 141 1 141 
16712 146 1 146 
17919 151 0 0 
19125 156 2 312 
20332 161 0 0 
21539 166 0 0 
22746 170 1 170 
23953 175 1 175 
Total = 257 14879 
Mean Diameter = 57.89494 
 






SEM image of nanoparticles 
  
SEM image of nanoparticles after 
processing by ImageJ 






Region 4. Contd… 
 
Size Distribution of nanoparticles: 
 
Area Dia Count Dia * Count 
1023 36 147 5292 
2437 56 54 3024 
3851 70 28 1960 
5266 82 18 1476 
6680 92 15 1380 
8095 102 10 1020 
9509 110 3 330 
10924 118 5 590 
12338 125 1 125 
13753 132 3 396 
15167 139 5 695 
16582 145 0 0 
17996 151 0 0 
19410 157 0 0 
20825 163 1 163 
22239 168 1 168 
23654 174 1 174 
25068 179 0 0 
26483 184 0 0 
27897 189 1 189 
Total = 293 16982 
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Literature and works of other scientists working on the same the topic.
• Write protocols to synthesize and characterize the nanoparticles, and collagen 
membranes.  
• Set up, install and troubleshoot a number of analytical and formulation equipment 
like HPLC, GC, GC-MS, Lyophilizer, Centrifuge, and Ultra-Sonifier. 
• Develop and validate methods to run analytical equipment like GC, GC-MS, and 
SEM.  
• Organize and compile experimental data for advisor review and formal 
publication submission.  
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Topical delivery by eye drops, which accounts for approximately 90% of all ophthalmic 
formulations, is extremely inefficient. Only approximately 5% of the drug applied as 
drops penetrates the outer layer of the eye and reaches the target, while the rest is lost due 
to tear drainage. A number of conditions like glaucoma, conjunctivitis, and proliferative 
retinopathy need a sustained release of drug inside the eye for drug to be therapeutically 
effective. In addition to eye drops, other ocular drug delivery systems include drug-
loaded liposomes or nanoparticles and drug-loaded contact lenses (hydrogels). Particle 
drug delivery systems also have difficulty penetrating the outer layer of the eye and can 
be lost before the drug can be released. Contact lens delivery systems often show a burst 
release with poor release over long periods of time.  
To improve sustain delivery of drugs to the eye, we have designed a novel system that 
includes drug-loaded nanoparticles suspended within a thin, membrane that can be 
attached to a standard commercial-grade contact lens for support. The lens system will 
provide constant contact with the eye's surface and the particles will supply a continuous 
release of medication, resulting in more drug reaching the target. First, PLGA 
nanoparticles, synthesized by the emulsion solvent evaporation technique, are loaded 
with the hydrophobic drug lidocaine. Next, the nanoparticles are loaded within a thin, 
collagen membrane that can be stored dried, and later rehydrated and attached to a 
contact lens for delivery to the eye.  
Drug loading and drug release rates must be controlled within the novel delivery system 
in order to ensure that therapeutic levels of the drug are delivered safely to the eye. The 
PLGA nanoparticles were found to be irregular in shape, 247 nm in diameter, and 
contained 5.17 wt% of lidocaine.  The nanoparticles loaded into the collagen membrane 
did not have a significant effect on light transmittance through the membrane, compared 
to a commercially available contact lens.  For initial drug release in the first 48 hours, the 
complete lens system, nanoparticles only, and collagen membrane only released 21.8%, 
53.0% and 7.6% of the initial drug loading, respectively.  For the first 400 hours tested, 
the complete lens system, nanoparticles only, and collagen membrane only released 
20.8%, 63.9 and 7.0% of the initial drug loading, respectively. 
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